Skip to content
DataLookout
Menu

NCT07901413

Evaluation of ICP-B381 in Patients With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Primary endpoint(s) modified
    • Start date changed from estimate of Nov 2026 to Oct 30, 2026
    • Secondary endpoints revised (21)
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

The type, severity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 [NCI-CTCAE V6.0]), relationship to the investigational product, and incidence rate of adverse event (AE) and serious advers
Timeframe: 2 years
The type, severity (assessed according to NCI-CTCAE V6.0), and incidence rate of dose limiting toxicity (DLT)
Timeframe: 2 years
Single-agent Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD)
Timeframe: 2 years
Participants with prostate cancer: Prostate-specific antigen (PSA50) response rate
Timeframe: 2 years
Participants with other tumor types: Investigator-assessed Objective response rate (ORR)
Timeframe: 2 years
The optimal dosing regimen for the subsequent study of ICP-B381
Timeframe: 2 years

Secondary (21)

Maximum Concentration (Cmax)
Time to Maximum Plasma Concentration (Tmax)
Half-life (T1/2)
Area Under the Serum or Plasma Concentration-Time Curve (AUC0-∞ and AUC0-t)
Apparent Clearance Rate (CL/F)
Show 16 moreShow less
Terminal Apparent Volume of Distribution (Vz/F)
Steady-state Pharmacokinetic Parameters
Objective response rate (ORR)
Disease Control Rate (DCR)
Duration of Response (DOR)
Participants with prostate cancer: radiographic progression-free survival (rPFS) evaluated by the Investigator according to RECIST V1.1 criteria (for soft tissue lesions) and PCWG3 criteria (for bone lesions)
Participants with prostate cancer: changes in serum PSA levels compared to baseline during the study: PSA50 response rate
Participants with prostate cancer: PSA90 response rate
Participants with prostate cancer:12-week PSA response rate
Participants with prostate cancer: time to PSA progression (TTPP)
Time to First Subsequent Therapy (TFST)
Overall Survival (OS)
Participants with prostate cancer: incidence rate of symptomatic skeletal event (SSE)
Participants with prostate cancer: time to first symptomatic skeletal event (TTSSE)
Incidence rate of anti-drug antibody (ADA) against ICP-B381
Types, severity (assessed according to NCI-CTCAE V6.0), relationship with the investigational product, and incidence rate of AE and SAE

Arms and interventions

ICP-B381Experimental

Drugs: ICP-B381

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China